Connect® MDS/AML Disease Registry

Connect MDS and AML Disease Registry: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

November 22, 2017

  • Clinical Trial Information

    Trial Contact: Caparas, Maria-Lourdes

    Trial Phone: 321.841.3498

  • IRB No: 13.144.09

    Protocol Abbrev: Connect MDS

    Principal Investigator: Daniel Ari Landau, MD

    Sub Investigators: Baidas, Said MD; Hajdenberg, Julio MD; Johnson, Tirrell MD; Kayaleh, Omar MD; Rostorfer, Regan MD; Sarriera, Jose MD; Thomas, Sajeve MD

    Age Group: Adult

    Secondary Protocol No: AZA-MDS-006

    Applicable Disease Sites: Leukemia ID: NCT01688011

  • Objective

    The purpose of the registry is to provide insights into treatment regimens of patients with newly diagnosed MDS or AML

  • Key Eligibility

    AML or MDS newly diagnosed